23-LEUK-23-CC: ACE-536-MF-002, A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy

Grants and Contracts Details

StatusActive
Effective start/end date11/27/23 → 11/27/25

Funding

  • Celgene: $18,731.00